weekly_roundup
BioTechSign Daily Catalyst Roundup - November 15, 2026
Top BioTechSign catalyst names today: YMAB, EYPT, SRPT, SMMT, IBRX, IDYA. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 15, 2026
Daily Biotech Catalyst Digest: November 15, 2026
YMAB leads the current BioTechSign screen at 98.3/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| YMAB | Y-mAbs Therapeutics | 98.3 | A | clinical activity 100%, publication signal 15% |
| EYPT | EyePoint, Inc. | 84.2 | A | clinical activity 100%, short interest 70%, dilution risk 43% |
| SRPT | Sarepta Therapeutics | 84.2 | A | publication signal 100%, clinical activity 96%, short interest 70% |
| SMMT | Summit Therapeutics Inc. | 82.7 | A | publication signal 100%, clinical activity 100%, short interest 90% |
| IBRX | ImmunityBio, Inc. | 80.7 | A | publication signal 100%, clinical activity 100%, short interest 90% |
| IDYA | IDEAYA Biosciences | 79.7 | B | publication signal 100%, clinical activity 100%, short interest 50% |
Recent Grade-Change Queue
- SMMT (Summit Therapeutics Inc.) currently grades A with a 82.7/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 90%.
- IBRX (ImmunityBio, Inc.) currently grades A with a 80.7/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 90%.
- VRTX (Vertex Pharmaceuticals) currently grades B with a 67.1/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, PDUFA timing 90%.
- NVO (Novo Nordisk) currently grades B with a 73.3/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 12%.
- BNTX (BioNTech SE) currently grades B with a 74.0/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 15%.
- BMRN (BioMarin Pharmaceutical) currently grades B with a 74.5/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 30%.
- TGTX (TG Therapeutics) currently grades B with a 77.7/100 catalyst score. Main inputs: clinical activity 100%, short interest 70%, dilution risk 11%.
- AZN (AstraZeneca) currently grades C with a 52.0/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 12%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.